Induced cross-resistance of BRAF^V600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment.

ABSTRACT: The maximum response and 10-year survival rate for metastatic melanoma patients treated with standardised chemotherapy is still less than 15% and 10%, respectively. In contrast, oncogene targeting was found a promising tool for killing of BRAF^V600 mutated melanoma cells. Nevertheless, despite improved response and survival rates, resistance acquisition remains an ongoing problem. In this context, the impact of chronic BRAF inhibition on the efficacy of commonly applied cytostatics is still unknown. In our study, human melanoma cells with BRAF^V600E mutation were treated with chemotherapeutics and a BRAF inhibitor. Resistance patterns were analysed by microelectrode array-based impedance spectroscopy, XTT and flow cytometric apoptosis/proliferation assay. BRAF^V600E

SUBMITTER: Erdmann S 

PROVIDER: S-EPMC6328535 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature